Emcure Pharmaceuticals: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

What happened

Emcure Pharmaceuticals (EMCURE) filed a disclosure with the exchanges on 2 October 2026 at 09:31 PM titled "Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company".

Company snapshot

Emcure Pharmaceuticals is a mid-cap company in the Healthcare sector, with a market value of about ₹36,885 crore.

The stock last traded at ₹1,944.6, against a 52-week range of ₹1,299.7–₹2,100.7 (7.4% below the high).

Before this filing the shares had moved +5.3% over the month and +5.7% over three months. Average daily turnover over the last 20 sessions was about ₹41.07 crore.

Promoters held 77.83% at the end of Q1 FY27, down 0.04% points from the previous quarter; 0.04% of promoter shares were pledged. Foreign institutions owned 4.88% and domestic institutions 8.46%.

What history shows

BCEIE has no earlier litigation filing from this company on record since May 2026.

Across 16 similar disclosures by other Healthcare companies, shares moved −0.6% on average the next day and −0.2% over five days; 31% of them rose the next day.

Market-wide, 531 litigation filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 35% rising.

Past reactions describe what happened before; they are not a forecast.

In the news

Recent coverage elsewhere (links open the original publisher):

• Emcure Pharmaceuticals Ltd Key Financial Ratios – Valuation, Profitability & More — valueresearchonline.com, 21 Sept 2026
• Rajiv Dua Joins Emcure Pharmaceuticals as GM & Head – PMO & Program Management, Gennova Biopharma — hrtoday.in, 2 Oct 2026
• Emcure Pharmaceuticals Share Price Falls: Fundamental View — Univest, 30 Sept 2026
• Emcure Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 — marketscreener.com, 23 Sept 2026
• Emcure Pharmaceuticals recommends ₹3.60 dividend; AGM on Sept 21 — scanx.trade, 21 Sept 2026

Source

• Exchange filing (PDF)